By binding simultaneously to CD3 receptors on T cells and HER2 receptors on tumor cells, it creates a bridge between these cells, potentiating the T-cell cytotoxic effect against HER2-positive tumor cells [198]. The gene discussed is ERBB2; the disease is neoplasm.